AOD9604 (Fragment 176-191): sourcing, documentation and price

AOD9604 (Fragment 176-191) is a synthetic peptide corresponding to the C-terminal region of human growth hormone, specifically residues 176 through 191, and it is classified as a research peptide rather than an approved therapeutic. It is also written as AOD-9604, AOD 9604, hGH fragment 176-191, and anti-obesity drug 9604, the last of these being a historical label rather than a description of any established clinical action. The evidence block supplied for this page does not give a residue-by-residue sequence, a molecular formula or a molecular weight, so none are stated here; those values should be taken from the certificate of analysis accompanying a specific lot rather than from a general page. The work that centres on this fragment concerns growth hormone receptor and lipolytic signalling pathways, and the literature reviewed in the evidence block places it among unapproved peptides marketed directly to patients [1][2].

Because the fragment is a short chain of amino acids, it sits in the pharmacological space between small-molecule drugs and large proteins, a niche the reviewed literature describes as distinct and increasingly populated in sports medicine [1][2]. That positioning matters for sourcing: a short synthetic peptide is defined by its sequence and its purity, both of which are lot-specific, and neither of which can be inferred from a product name alone. The sections below set out what the research record contains, where that record is animal-only or in vitro, and what documentation a laboratory buyer should expect to receive with a shipment.

Research Studies

AOD9604 and its classification among unapproved peptides

The review underpinning this page examined the pharmacological mechanisms, safety profiles and regulatory status of peptides marketed directly to patients, and it grouped AOD-9604 with compounds operating largely outside regulatory oversight [1][2]. The same review notes that while a number of peptide drugs have passed a rigorous approval process evaluating both safety and efficacy, a parallel gray market has emerged for unapproved compounds [1][2]. For a laboratory, the practical consequence is that AOD9604 arrives without the regulatory scaffolding that accompanies an approved drug: no approved indication, no regulator-reviewed safety database, and no standardised clinical labelling. Characterisation therefore falls entirely to the supplier's analytical documentation.

AOD9604 and the growth hormone fragment literature

The fragment is defined by its relationship to human growth hormone rather than by an independent pharmacological identity. The reviewed literature treats it as a fragment of that parent molecule and discusses it within the broader category of peptides promoted for performance and recovery purposes [1][2]. This framing is important when reading primary papers, because early work on the fragment is frequently reported in animal models and in isolated cell systems rather than in human participants. Where a finding comes from an animal model, it should be described as such, and it should not be carried across to human expectations.

AOD9604 and lipolytic signalling in animal and in vitro models

Work on growth hormone fragments has historically centred on lipolytic signalling, and the evidence block for this page supports only the general statement that the compound's pharmacological mechanism is discussed in the reviewed literature [1][2]. No specific effect size, dose, species or assay result is provided in the evidence block, so none is reported here. A laboratory evaluating the fragment should treat the mechanistic literature as a starting point for its own assay design rather than as a settled account, and should verify the model system used in any paper it relies on, since findings from isolated cells and from whole animals answer different questions.

AOD9604 and the sports medicine context

The reviewed literature situates peptides such as AOD-9604 within sports medicine, where demand for accelerated injury recovery and performance enhancement has driven rapid expansion in use [1][2]. That context is commercial and cultural as much as it is scientific: the review describes patient demand as a driver of the market, and it describes the unapproved segment of that market as operating outside regulatory oversight [1][2]. For research supply purposes, the relevant takeaway is that demand-side pressure does not generate evidence, and a compound's popularity in a market segment is not a finding about its activity.

AOD9604 and the limits of the current evidence base

The evidence block supplied here does not contain a human trial of AOD9604, a pharmacokinetic study, or a safety dataset. It contains a review that names the compound among unapproved peptides and discusses its mechanism and regulatory status in general terms [1][2]. Any page that presents human outcomes, dosing schedules or efficacy claims for this fragment is going beyond what this evidence supports. The honest summary is that the mechanistic and regulatory discussion exists, and the clinical evidence base for the fragment, as reflected in this block, does not.

AOD9604 and documentation expectations for laboratory supply

Because the compound is unapproved and unregulated in the way an approved drug is, the analytical paperwork is the product. A laboratory purchasing AOD9604 should expect a lot-specific certificate of analysis stating the identity of the material, the purity determined by a chromatographic method, and the analytical technique used. Where a supplier cannot state the method, the purity figure carries little weight. The table below sets out the documentation items that matter and why.

AOD9604 and how it compares with approved peptide therapeutics

The reviewed literature draws a clear line between peptides that have undergone a rigorous approval process evaluating safety and efficacy and those that have not [1][2]. AOD-9604 falls on the unapproved side of that line. The comparison below is about regulatory status and evidence type, not about activity, and it is the distinction a laboratory should keep in view when deciding what a given compound can and cannot be used to demonstrate.

AOD9604 and sourcing considerations for research laboratories

Sourcing an unapproved peptide is a documentation exercise before it is a price exercise. The reviewed literature's central observation, that a gray market operates largely outside regulatory oversight, means the buyer's diligence substitutes for the oversight that would otherwise apply [1][2]. In practice that means confirming the supplier states a lot-specific purity with a named method, that the material is sold explicitly for laboratory research rather than for any other purpose, and that the catalogue entry does not make claims the evidence cannot support. Price should be compared only between lots of equivalent stated purity, because a lower figure attached to an unstated method is not a like-for-like comparison.

AOD9604 and catalogue presentation

The catalogue entry for this compound is AOD9604 (Fragment 176-191), supplied as a 5 mg presentation for laboratory research use. The entry is a supply listing, not a therapeutic one, and it should be read alongside the lot documentation rather than instead of it. Laboratories comparing suppliers should request the certificate of analysis for the specific lot on offer before evaluating price, since purity and method are the variables that determine whether two listings are comparable at all.

If you are reading this for personal health reasons

This material is sold for laboratory research only, and nothing on this page is medical advice. We do not provide dosing guidance, and we do not provide guidance on using this compound in a person. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
• [2] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
• [3] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/